Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity Score Matched Study
Al Sulaiman et al.,
Ascorbic Acid as an Adjunctive Therapy in Critically Ill Patients with COVID-19: A Multicenter Propensity..,
Research Square, doi:10.21203/rs.3.rs-354711/v1 (Preprint)
Retrospective 158 critically ill patients receiving vitamin C and propensity matched controls, showing mortality OR 0.77 [0.48-1.23], and statistically significantly lower thrombosis, OR 0.42 [0.18-0.94]. 1000mg of vitamin C was given daily.
risk of death, 14.9% lower, RR 0.85, p = 0.27, treatment 46 of 142 (32.4%), control 59 of 142 (41.5%), NNT 11, odds ratio converted to relative risk, PSM.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Al Sulaiman et al., 2 Apr 2021, retrospective, propensity score matching, Saudi Arabia, preprint, 12 authors.
Abstract: Ascorbic Acid as an Adjunctive Therapy in Critically
Ill Patients with COVID-19: A Multicenter Propensity
Score Matched Study
Khalid Al Sulaiman ( alsulaimankh@hotmail.com )
King Abdulaziz Medical City
Ohoud Al Juhani
King Abdulaziz University
Khalid Bin Salah
King Abdulaziz Medical City
Hisham A. Badreldin
King Abdulaziz Medical City
Abdullah Al Harthi
King Abdulaziz Medical City
Mohammed Alenazi
King Saud bin Abdulaziz University for Health Sciences
Aisha Alharbi
King Abdulaziz University Hospital
Rahmah Algarni
King Abdulaziz University Hospital
Shmeylan Al Harbi
King Abdulaziz Medical City
Abdullah Alhammad
King Saud University
Ramesh Vishwakarma
King Abdullah International Medical Research Center
Sarah Aldekhyl
King Abdulaziz Medical City
Research Article
Keywords: COVID-19, SARS-CoV-2, Ascorbic Acid, Vitamin C, Vitamins, Critically ill, Intensive Care Units
(ICUs), 30-days ICU mortality
Posted Date: April 2nd, 2021
Page 1/17
DOI: https://doi.org/10.21203/rs.3.rs-354711/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Page 2/17
Abstract
Background:
Ascorbic acid represents an appealing option for clinicians to utilize in the context of a global health
pandemic of COVID-19 patients due to its proposed clinical efficacy, relative safety, and low cost.
Objectives:
The aim of this study was to evaluate the efficacy and safety of using ascorbic acid in supplemental
dose as adjunctive therapy in critically ill patients with COVID-19.
Methods:
This was a multi-center, non-interventional, retrospective cohort study. All critically ill adult patients
admitted to ICU with a confirmed COVID-19 between March 1st to December 31st, 2020 were included in
the final analysis. The study was conducted at two large governmental tertiary hospitals in Saudi Arabia.
The purpose was to investigate the association between clinical outcomes with ascorbic acid use as an
adjunctive therapy in COVID-19 after propensity score matching using baseline severity scores, systemic
use of corticosteroids and study centers.
Results:
A 739 patients were included in this study; 296 patients were included after propensity score matching.
There was no association between the administration of ascorbic acid and in-hospital mortality nor 30day ICU mortality (OR (95%CI): 0.77 (0.476, 1.234), p-value=0.2738 and OR (95%CI): 0.73 (0.438 ,1.204),
p-value=0.215 respectively). Using ascorbic acid was associated with lower incidence of thrombosis
compared with the non-ascorbic acid group (6.1% vs. 13% respectively); OR (95%CI): 0.42 (0.184, 0.937),
p-value=0.0342).
Conclusion:
Supplemental dose of ascorbic acid as an adjunctive therapy in COVID19 critically ill patients was not
associated with mortality benefits; but associated with lower incidence of thrombosis. Further studies are
required to confirm these findings.
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit